Type of non Hodgkin's lymphoma-Follicular lymphoma Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Follicular lymphoma Posts on Medivizor

Evaluating the impact of quality of life at diagnosis on patient outcomes for aggressive lymphoma

Posted by on Feb 9, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated whether quality of life (QOL) scores impact outcomes for patients with aggressive lymphoma. This study concluded that QOL scores at diagnosis may predict survival outcomes for these patients. Some background The International Prognostic Index (IPI) is the most widely used tool to predict survival outcomes for...

Read More

Predicting the effects of stem cell transplant in older patients with non-Hodgkin lymphoma.

Posted by on Feb 9, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effects of stem cell transplant for non-Hodgkin lymphoma (NHL) in older patients. The main finding was that patients who responded to chemotherapy had better outcomes after stem cell transplant. Some background Stem cell transplant is often used to treat NHL. This involves the transfer of healthy cells to a...

Read More

Long-term outcomes of radioimmunotherapy for patients with follicular lymphoma

Posted by on Jan 28, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of radioimmunotherapy (RIT) in patients with follicular lymphoma (FL). This study concluded that RIT is a safe and effective long-term treatment option for these patients. Some background FL is the most common type of non-Hodgkin’s lymphoma. The current standard first-line treatment for...

Read More

Evaluating second-line rituximab-bendamustine treatment for patients with follicular lymphoma

Posted by on Jan 12, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of the BR (bendamustine, rituximab) regimen as a second-line treatment for patients with follicular lymphoma (FL) who had disease progression (tumor growth or spread) after chemoimmunotherapy. The study concluded that this regimen was effective in these patients. Some background...

Read More

Evaluating the long-term outcomes of Zevalin for patients with advanced B cell lymphoma

Posted by on Jan 10, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of patients with advanced (stage 3 – 4) non-Hodgkin’s lymphoma (NHL) who received radioimmunotherapy before allogeneic stem cell transplantation (alloSCT). This study concluded that this treatment regimen improved survival in most of these patients. Some background AlloSCT involves...

Read More

Safety and effectiveness of the biosimilar CT-P10 compared to rituximab in patients with follicular lymphoma

Posted by on Jan 3, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the safety and effectiveness of CT-P10 (Truxima) compared to rituximab (Rituxan) in the treatment of follicular lymphoma. Researchers found that CT-P10 had similar safety and effectiveness as rituximab in these patients. Some background Lymphoma is a cancer of the immune system. It is often treated with drugs...

Read More

Does PET/CT scanning affect treatment and survival of patients with lymphoma?

Posted by on Dec 30, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the effect of PET/CT scanning on the treatment and survival of patients with lymphoma. Researchers found that PET/CT improved the management plan and survival of these patients. Some background PET/CT are types of scans that detect changes in cells and tissues inside the body. They can be used to check the sites of...

Read More

Evaluating the safety and effectiveness of axicabtagene ciloleucel for unresponsive B-cell lymphoma

Posted by on Dec 30, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the safety and effectiveness of axicabtagene ciloleucel (AC; Yescarta) in the treatment of unresponsive B-cell lymphoma. Researchers found that AC is a safe and effective treatment for these patients. Some background B-cell lymphoma is a cancer of cells in the immune system. It is treated with medication that targets...

Read More

Evaluating the impact of early PET/CT scanning on survival in patients with lymphoma after stem cell transplant

Posted by on Dec 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the impact of early FDG PET/CT scanning on the survival of patients with lymphoma after allogeneic stem cell transplantation (alloSCT). This study concluded that having positive scan results at 3 months after alloSCT may highly predict relapse and poor survival in these patients. Some background An alloSCT is a...

Read More

Evaluating the impact of early PET/CT scanning on survival in patients with lymphoma after stem cell transplant

Posted by on Dec 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the impact of early FDG PET/CT scanning on the survival of patients with lymphoma after allogeneic stem cell transplantation (alloSCT). This study concluded that having positive scan results at 3 months after alloSCT may highly predict relapse and poor survival in these patients. Some background An alloSCT is a...

Read More

Evaluating the risk of heart complications after anthracycline treatment for patients with DLBCL or FL

Posted by on Nov 30, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the risk of developing congestive heart failure (CHF; the muscle of the heart becomes weak and does not pump blood efficiently) in patients with non-Hodgkin’s lymphoma (NHL) after first-line chemoimmunotherapy. This study concluded that treatment containing anthracyclines was associated with a significantly higher...

Read More

Evaluating lenalidomide plus everolimus for relapsed or refractory lymphoma

Posted by on Oct 28, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of lenalidomide (Revlimid) plus everolimus (Afinitor) in pretreated patients with relapsed (recurrent) or refractory (does not respond to treatment) lymphoma. This study concluded that this combination was well-tolerated and showed promising effectiveness in these patients. Some...

Read More